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Micropositron emission tomographyDespite intensive research, the pathways that mediate calcium (Ca2+)-stimulated glucose transport in striated
muscle remain elusive. Since the sarcoplasmic reticulum calcium ATPase (SERCA) pump tightly regulates
cytosolic [Ca2+], we investigated whether the SERCA pump is a major regulator of cardiac glucose transport.
We used healthy and insulin-deﬁcient diabetic transgenic (TG) mice expressing SERCA1a in the heart. Active
cell surface glucose transporter (GLUT)-4 was measured by a biotinylated photolabeled assay in the intact per-
fusedmyocardium and isolatedmyocytes. In healthy TGmice, cardiac-speciﬁc SERCA1a expression increased ac-
tive cell-surface GLUT4 and glucose uptake in themyocardium, aswell aswhole body glucose tolerance. Diabetes
reduced active cell-surface GLUT4 content and glucose uptake in the heart of wild type mice, all of which were
preserved in diabetic TG mice. Decreased basal AS160 and increased proportion of calmodulin-bound AS160
paralleled the increase in cell surface GLUT4 content in the heart of TG mice, suggesting that AS160 regulates
GLUT trafﬁcking by a Ca2+/calmodulin dependent pathway. In addition, cardiac-speciﬁc SERCA1a expression
partially rescues hyperglycemia during diabetes. Collectively, these data suggested that the SERCA pump is a
major regulator of cardiac glucose transport by an AS160 dependent mechanism during healthy and insulin-
deﬁcient state. Our data further indicated that cardiac-speciﬁc SERCA overexpression rescues diabetes
induced-alterations in cardiac glucose transport and improves whole body glucose homeostasis. Therefore, ﬁnd-
ings from this study provide novel mechanistic insights linking upregulation of the SERCA pump in the heart as a
potential therapeutic target to improve glucose metabolism during diabetes.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetes, which has reached epidemic proportion, causes multi-
organ dysfunction and is a signiﬁcant risk factor for the development
of cardiovascular disease. Diabetes results in part from decreased
glucose uptake into insulin-sensitive tissues (i.e., striated muscle and
adipose tissue) due to a lack of insulin production or action. The trans-
location of the glucose transporter 4 (GLUT4), the major isoform, from
an intracellular pool to the cell surface (active site) is the rate limiting
step in glucose uptake, and is independently stimulated by insulin-
and Ca2+/contraction-dependent processes [1,2]. However, despite
intensive research (primarily in skeletal muscle and adipose tissue),
the pathways mediating insulin- and to a larger extent contraction/
Ca2+-stimulated glucose uptake, remain elusive as well as theircal Sciences, 283 McElroy Hall,
el.: +1 405 744 8089; fax: +1
Lacombe).pathogenic contribution to diabetes [2]. Although it has long been sug-
gested that increases in intracellular Ca2+ levels, even at concentrations
too low to induce contractions, provide the signal to activate GLUT4
translocation in skeletal muscle [1,3], independently of insulin, less is
known about Ca2+-mediated glucose transport in the heart. Indeed,
the role of Ca2+ has primarily been investigated in the context of
insulin-stimulated glucose uptake and remains controversial. Since the
sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) pump is a ubiqui-
tous protein that tightly regulates cytosolic [Ca2+], it could be a major
regulator of glucose transport via Ca2+-mediated signaling pathways.
However, while it has been demonstrated that SERCA pump dysfunc-
tion contributes to diabetic cardiomyopathy [4–6] and that increased
cardiac SERCA2a expression results in increased glucose oxidation [7],
the regulation of GLUT trafﬁcking by the SERCA pump has not been in-
vestigated in the healthy and diabetic myocardium. Since the SERCA
pump provides the only mechanism to maintain SR/ER Ca2+ stores in
muscle and non-muscle cells, it could therefore potentially regulate
glucose homeostasis through an insulin-independent pathway. Further-
more, although the downstream signaling pathways regulating glucose
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(AS160) is the most distal signaling protein implicated in both insulin
and Ca2+-mediated GLUT4 translocation in skeletal muscle [8,9].
While there is some evidence that alteration in AS160 activation is
one of the mechanisms for the impaired GLUT trafﬁcking in skeletal
muscle during insulin resistance and diabetes [10–12], some results
are controversial [10–12]. In addition, a similar pathogenic role in the
diabetic heart is unknown.
The present study employed a mechanistic and integrative
approach to determine whether the SERCA pump is a regulator of
cardiac glucose transport, independently of insulin, in the healthy
and diabetic myocardium. In the present study, we reported that
increased SERCA pump expression provides a main mechanism reg-
ulating cardiac GLUT4 trafﬁcking in an insulin-deﬁcient state. Our
data further suggest that cardiac-speciﬁc SERCA1a expression not
only rescues impaired cardiac glucose transport during diabetes
but also improves whole body glucose homeostasis. This evidence
of a relationship between the SERCA pump, myocardial glucose
uptake and whole body glucose homeostasis could have important
implications for the identiﬁcation of novel therapeutic targets for
the diabetic population.
2. Material and methods
2.1. Animals
All procedures were approved by the Oklahoma State University
and Ohio State University Institutional Animal Care and Use Commit-
tees. We used a transgenic (TG) mouse model expressing the
(skeletal) SERCA1a isoform in the heart. Brieﬂy, SERCA1a cDNA was
linked to the mouse cardiac α-MHC promoter, and SERCA1a+/+
male mice were generated, which were then bred with FVB/N female
wild type (WT) mice to establish a germ line transmission, while
avoiding backcrossing [13–16]. Each mouse was genotyped when it
was weaned and tail clips were kept to reconﬁrm the genotype by
PCR reactions. We previously reported that the SERCA1a isoform
posseses faster SR Ca2+ transport kinetics and can substitute both
structurally and functionally to SERCA2a in the heart. In addition,
the SERCA1a isoform interacts with phospholamban, and total and
phosphorylated (at Thr17 site) phospholamban expression is re-
duced in the SERCA1a (+/+) hearts. As a consequence, the rate of
SR Ca2+ transport activity, SR Ca2+ content and the amplitude of
Ca2+ transient are enhanced in these TG mice [15,16]. Previous
studies suggested that SERCA1a (+/+) hearts were markedly
protected against I/R injury, suggesting that the expression of
SERCA1a isoform reduces post-ischemic calcium overload and thus
provides potent myocardial protection [14]. However, whether sim-
ilar cardioprotective effects occur during diabetes is unknown.
Therefore, we used four groups of mice (18/group, age 12–16
weeks): healthy TG mice and their WT littermates, and insulin-
deﬁcient diabetic (Dx) TG mice (induced by 3 consecutive intraperi-
toneal streptozotocin (STZ) injections of 65–95 mg/kg every 48 h)
and their Dx WT littermates.
2.2. Fasting glucose concentration and glucose tolerance tests
Venous blood was drawn weekly from the facial vein for measure-
ment of glucose, using a glucometer (Bayer Contour, Tarrytown, NY)
on mice that previously fasted overnight [17]. Intraperitoneal glucose
tolerance tests (IPGTT) were performed on (healthy and diabetic) WT
and TG, that fasted for 6 h prior to testing. After intraperitoneal injection
of 1.5 g/kg glucose bolus (dissolved in 300 μl of citrate buffer), venous
blood were drawn from the facial vein, for measurement of glucose
(as described above) at time points 0, 20, 40, 60 and 120 min following
the glucose bolus.2.3. Echocardiography
Echocardiography was performed in mice lightly anesthetized
(1–1.5% isoﬂurane in O2), using the Vevo 2100 echocardiograph sys-
tem (with a 30 MHz probe), as previously described [16,17]. Brieﬂy,
ventricular structure and function were assessed by measuring left
ventricular (LV) end-diastolic and end-systolic internal diameter from
M-mode tracings, and systolic function was assessed by measuring
LV ejection fraction. Color ﬂow guided, pulsed-wave Doppler imaging
was recorded for pulmonary artery, pulmonary venous, mitral and aor-
tic ﬂows. Pre-ejection period and ejection time of the pulmonary artery
were measured by pulsed-wave Doppler recordings to assess systolic
function of the right ventricle, and the ratio of pre-ejection to ejection
time was calculated. Diastolic function was evaluated by color ﬂow-
guided, pulsed-wave Doppler recordings of the maximal early and late
diastolic transmitral ﬂow velocities. Animals were maintained on a
heating table to maintain normothermia during these physiologic
measurements. All echocardiographic examinations were conducted
by the same investigator (VAL). Average values were obtained from
the measurement of 3–5 consecutive cardiac cycles.
2.4. Micropositron emission tomography (microPET)
Myocardial glucose uptake was assessed by 18ﬂuorodeoxyglucose
(FDG) activity measured by microPET in mice that fasted for 3 h prior
to injection of 30 MBq of 18FDG into the tail vein. The mice were kept
warm with a heating pad from the point of injection until full recovery
from anesthesia. One hour following injection the mice were initially
anesthetized by placing them into a bell-shaped chamber infused with
1.5% isoﬂurane, after which they were kept under anesthesia using a
nose-cone and breathing ~0.8% isoﬂurane for the duration of the
microPET imaging procedure. 3D MicroPET imaging was performed on
mice in the prone position using Siemens Inveon™ (Siemens, Erlangen
Germany) imaging system 1 h following injection, and took ~10 min
per animal to acquire. FDG uptake for each region of interest (ROI;
e.g., heart, bladder)was evaluated from an averaged image of the entire
FDG scan and calculated using the following equation: voxel valuewith-
in ROI (Mbq/ml)/activity injected (Mbq)/body weight (mg) [18].
2.5. Isolation of cardiac myocytes
Animals were deeply anesthetized with intraperitoneal injection of
pentobarbital sodium (140mg/kg), and the heart was rapidly removed.
Isolation of cardiac myocytes was performed by retrograde perfusion of
the heart using a Langendorff apparatus, as previously described [5,17,
19]. Ventricularmyocyteswere obtained by enzymatic perfusion (Colla-
genase, Worthington, NJ, USA), with a minimum yield of 70% live cells
being considered acceptable.
2.6. Protein extraction and Western blotting
Striated muscles were rapidly collected, ﬂash-frozen in liquid
nitrogen and stored at−80°C until further analysis. Total tissue extracts
(for measurement of SERCA and total and phosphorylated AS160) were
obtained by homogenizing frozen tissue samples in buffer [20mMTris–
HCl, 5 mMEDTA, 10mM sodium pyrophosphate, 100 mM sodium ﬂuo-
ride, 2 mM sodium vanadate, 3 mM benzamidine, 1% Ipegal, and prote-
ase and phosphatase inhibitors (Sigma, St. Louis, MO)]. Homogenates
were then centrifuged at 14,000 g for 10 min at 4 °C, following which
the supernatant was extracted, analyzed for protein content by BCA
(Thermo Scientiﬁc, Ashville, NC), and then stored at −80 °C until
Western blot analysis [5]. Crude extracts of membrane-enriched ven-
tricularmyocardium and gastrocenemius skeletal muscle (formeasure-
ment of GLUT4) were obtained as follows: frozen tissue samples were
homogenized in buffer, which contains (mM): sucrose 210, NaCl 40,
EDTA 2, HEPES 30, and protease inhibitor (Sigma, St. Louis, MO). The
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KCl 1.17 mM. The crude plasma membrane-enriched fraction was
then recovered by centrifugation at 100,000 g for 90 min at 4 °C. Pellets
were resuspended with a solution containing (mM): Tris·HCl 10, and
EDTA 1. After addition of SDS (16%, 0.33 total volume) the samples
were centrifuged at 3000 g for 25 min, and the supernatant was ana-
lyzed by BCA and stored at−80 °C until analysis [5,17,19,20].
Protein extracts were resolved by SDS-PAGE electrophoresis,
electrophoretically transferred to PVDF membranes, and subjected to
immunoblotting as previously described [5,11,17,19,20]. Membrane
proteins were incubated with rabbit polyclonal GLUT4 (1:7500,
AbD Serotec, Raleigh, NC), SERCA1a and SERCA2a (1:1000, Sigma,
St Louis, MO), and total and phosphorylated AS160 (1:1000, Cell
Signalling, Beverly, MA) antibodies, with subsequent appropriate
secondary antibodies conjugated to horseradish peroxidase. Quanti-
tative determination of protein was performed by autoradiography
after revealing the antibody-bound protein by enhanced chemi-
luminescence reaction. Equal protein loading was conﬁrmed by
reprobing each membrane for calsequestrin protein expression
(1:2500, Millipore, Billerica, MA) or MemCode reversible protein
staining (Thermo Scientiﬁc, Ashville, NC).SERCA1a
TG
TG WT
TG TGWT WT
DxCon
A
B2.7. Calmodulin-binding assay
After SDS-PAGE and transfer to PVDF, membranes were blocked in
buffer A (50mMTris–Cl, pH 7.5, 200mMNaCl, and 50mMMgCl2) con-
taining 1% BSA and 0.5 mM CaCl2 for 1 h, and then treated with
100 ng/ml biotinylated calmodulin (CaM; Calbiochem) in buffer A for
2 h, as described previously [8,21]. The membranes were washed in
buffer A with CaCl2 containing 0.05% Tween 20. CaM association was
detected by incubating the membranes with streptavidin-HRP
(1:50,000, Invitrogen) and with chemiluminescent substrate. The data
was normalized to total AS160, which was quantiﬁed by stripping the
membrane in buffer A containing EGTA (5 mM) and then incubating it
with anti-AS160 antibody, as described above.0
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Fig. 1. Transgenic mice demonstrate prominent SERCA1a gene and protein expression in
both healthy and diabetic hearts. A) PCR analysiswith tail samples from offspring of trans-
genic breeders, showing a distinct band of SERCA1a gene in the transgenic (TG) but not in
the wild type (WT) mice. B) Representative Western blot of SERCA-1a and 2a in cardiac
tissue. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase (loading control).
C) Mean ± SE of total SERCA protein content from type 1 diabetic (Dx) and littermate
healthy (Con)WT and TGmice (n= 5/group). * P b 0.05 vs. WT Con, † P b 0.05 vs. WT Dx.2.8. GLUT4 translocation to the cell surface
Isolated hearts underwent a 30-min baseline Langendorff perfusion
followed by 35 min of additional perfusion with or without insulin
(at physiologic concentration, 100 μU/ml) before photolabeling with
the cell surface impermeant biotinylated bis-mannose reagent
(300 μM bio-LC-ATB-BGPA, Toronto Research Chemicals Inc.), of
which the hexose group interacts speciﬁcally with the extracellular
binding site of GLUT [22]. This infusion technique produced homoge-
nous photolabeling of cell surface GLUT4 throughout the perfused
heart [23]. Total cardiacmembrane extracts of photolabeledmyocardial
tissue (“total lysate” fraction) were incubated with streptavidin bound
to 6% agarose beads (Pierce, Rockford, IL), which allows separation of
non-cell surface GLUTs (“unlabeled” or intracellular fraction) that
remain in the supernatant from cell surface GLUTs (“labeled” or sarco-
lemmal fraction), as previously described by our group [11,19,20,23].
The labeled GLUTs were dissociated from the streptavidin by heating
at 94 °C in laemmli sample buffer for 30 min prior to SDS-PAGE (12%
Tris–HCl polyacrylamide gel) and subsequent immunoblotting with
GLUT antibodies, as described above. In a separate set of experiments,
cardiac myocyteswere incubated for 20minwithout (basal) or with in-
sulin (100 μU/ml), Ca2+ (0.5 μM), isoproterenol (100 uM), caffeine
(10mM), the Ca2+ chelator BAPTA-AM (50 μM), or SERCA pump inhib-
itor (200 nM thapsigargin). Bio-LC-ATB-BGPA photolabeled compound
was then added to the incubationmedia and cross-linked to cell surface
GLUTs after 1 min. The cells were then washed with Tyrode, solubilized
in lysis buffer, and subjected to protein quantiﬁcation and Western
blotting as described above.2.9. Statistics
Differences between means were assessed by two-way repeated
measure ANOVA (for in vivo data with transgenic background and
diabetic status as treatment factors), two-way ANOVA (for in vitro
factors), one-way ANOVA (Fig. 3) or paired t-test (Fig. 2S), as appropri-
ate (Sigmastat, Jandel Scientiﬁc).When a signiﬁcant differencewas iden-
tiﬁed by ANOVA, post hoc tests were performed using the Student–
Newman–Keuls technique. Statistical signiﬁcance was deﬁned as
P b 0.05. Data are presented as mean ± SE.3. Results
3.1. TG mice have prominent SERCA protein expression in both healthy and
diabetic hearts
We used a TG mouse model overexpressing SERCA1a in the heart
and insulin-deﬁcient diabetic model induced by streptozotocin injec-
tion. Genotyping was conﬁrmed by PCR analysis of tail samples, as TG
mice displayed a distinct band of SERCA1a+/+ gene (Fig. 1A). We fur-
ther measured cardiac total SERCA protein expression by Western
Blot, which was increased by 55.8 ± 9.3 and 46.6 ± 5.7% in the healthy
and diabetic TG mice compared to healthy littermate WT mice, respec-
tively (P b 0.05, Fig. 1B&C).
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Although the SERCA pump and glucose transport are both critical for
maintenance of cardiac myocyte function, a mechanistic link has not
been established. Therefore, we ﬁrst measured GLUT4 protein expres-
sion from a cardiac crude membrane-enriched fraction of TG and WT
mice by Western blot. Insulin-dependent diabetes reduced cardiac
crude membrane GLUT4 content in WT mice, while cardiac-speciﬁc0
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Fig. 2. SERCA1a expression improves cardiac GLUT4 translocation to the myocardial cell
surface. A) SERCA1a expression increases GLUT4 protein content in a myocardial mem-
brane-enriched preparation (n = 6–12/group). B) Diabetes reduces active cell surface
GLUT4 protein content and SERCA1a expression rescues GLUT4 content in the heart of di-
abeticmice with insulin deﬁciency. C) Expression of SERCA1a in the heart increases active
cell surface GLUT4 in insulin-stimulated photolabeled diabetic myocardium. Top panels:
Western blots of myocardial GLUT4. Bottom panel: mean ± SE of cell surface GLUT4 pro-
tein content (n = 4–10/group). L; labeled fraction (i.e., cell surface pool); UL: unlabeled
fraction (i.e., intracellular pool); TL: total lysate. * P b 0.05 vs. WT Con, † P b 0.05 vs. WT
Dx, # P b 0.05 vs. basal conditions.Methods:Hearts fromhealthyWT and TGmice express-
ing SERCA1a were perfused with (+) or without (−) insulin (at physiologic concentra-
tion, 100 μU/ml, for 35 min) before photolabeling with bio-LC-ATB-BGPA.SERCA1a expression signiﬁcantly enhanced GLUT4 content in healthy
TG mice (Fig. 2A). As expected, there was no signiﬁcant change
in crude membrane GLUT4 protein content in skeletal muscle of
healthy or Dx TG mice (data not shown). These data suggested that
SERCA overexpression enhances cardiac GLUT4 translocation to the
plasma membrane. However, it is important to note that the crude
membrane extract contains total cellular membranes, and thus plasma
membrane-associated GLUT4 could not be differentiated from intracel-
lular membrane-associated GLUT4. Therefore, we used a biotinylation
assay in the perfused intact heart to reliably and speciﬁcally quantify
the proportion of active GLUT4 at the cell surface. Cardiac-speciﬁc
SERCA1a expression enhanced active cell surfaceGLUT4 protein content
in the healthy myocardium of TG vs. WT mice (Fig. 2B). In addition, di-
abetes decreased basal active cell surface GLUT4 in WT Dx mice com-
pared to healthy WT mice, while cardiac speciﬁc SERCA1a expression
restored active cell surface GLUT4 in TGDxmice (Fig. 2B). Finally, diabe-
tes impaired insulin-stimulated GLUT4 translocation inWTmice, which
was preserved in TG Dx mice (Fig. 2C).
Since we recently demonstrated that the amplitude of Ca2+ tran-
sient and SR Ca2+ content were enhanced by ~40% in our TG mice
[16], we further evaluated the role of SR Ca2+ cycling, through the
SERCA pump, in regulating GLUT4 trafﬁcking. To this end, we applied
the biotinylation assay in isolated healthy cardiac myocytes incubated
with various pharmacological agents. We showed that insulin and
Ca2+ stimulated GLUT4 trafﬁcking, while chelating intracellular Ca2+
with BAPTA-AMdecreased cell surface GLUT4 content (Fig. 3A). In addi-
tion, isoproterenol (a beta adrenergic agonist, which indirectly en-
hances SERCA activity) and caffeine (which induces SR Ca2+ release)
resulted in increased active cell surface GLUT4 compared to basal
unstimulated myocytes, while the SERCA pump inhibitor thapsigargin
decreased cell surface GLUT4 (Fig. 3B).
In order to further elucidate the downstream pathways regulating
glucose transport in the myocardium, we measured cardiac AS160 pro-
tein content by Western blot. SERCA overexpression decreased total
AS160 protein expression in the heart of healthy and diabetic TG mice
compared to healthy WT, while there were no differences in phosphor-
ylated AS160 (at the phospho-Akt-p sites) (Fig. 4A and B). To investi-
gate alternative mechanisms that regulate AS160 and thus GLUT
trafﬁcking independently of insulin, we also quantiﬁed the binding of
calmodulin (CaM) to AS160. Our data indicated a signiﬁcant increase
in the proportion of CaM-bound AS160 in both healthy and diabetic
TG mice compared to their respective WT (Fig. 4C).3.3. Cardiac-speciﬁc SERCA1a pump expression enhances myocardial
glucose uptake and whole body glucose homeostasis in diabetic subjects
In light of our results demonstrating increased GLUT4 translocation
in TG mice, we investigated whether SERCA overexpression would en-
hance cardiac glucose uptake, as measured by microPET (Fig. 5A,B).
Myocardial glucose uptake was increased in (healthy and Dx) TG
mice, compared to their respective WT (Fig. 5C).
Since the heart is one of the main organs to utilize glucose [24], we
investigated whether increased cardiac glucose uptake secondary to in-
creased SERCA expression could affectwhole body glucose homeostasis.
Glucose tolerance, measured by IPGTT, was enhanced in healthy TG vs.
littermate WT mice such that blood [glucose] was signiﬁcantly lower
in TG mice at 15, 30 and 45 min following an IPGTT (Fig. 6A). During
diabetes, cardiac-speciﬁc SERCA1a expression partially rescued the hy-
perglycemia such that blood [glucose] was signiﬁcantly higher in WT
Dx vs. TG Dx mice (Fig. 6B). To investigate whether a shift in cardiac
substrate toward increased glucose uptake could regulate whole body
glucose homeostasis, we performed linear regression analysis between
several cardiac glucose transport parameters and venous blood
[glucose]. Blood [glucose] was signiﬁcantly negatively correlated with
both active cell surface GLUT4 (P = 0.015, Fig. 6C) and in vivo glucose
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photolabeled cardiac myocytes for GLUT4. Bottom panels: mean ± SE of cell surface
GLUT4 content. Dx: diabetic, Con: healthy, WT: wild type, TG: transgenic, L; labeled frac-
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and TG mice.
There were no differences in body weight, which was increased
(P b 0.05) at 8 weeks in all groups compared to baseline (Fig. 1
Suppl.). In addition, systolic and diastolic function was similar in WT
vs. TGmice, both at baseline and 8weeks after the induction of diabetes
(Fig. 2 Suppl., Supplemental Tables 1 and 2).4. Discussion
Given the prevalence of diabetic cardiac complication and its associ-
ation with cellular Ca2+ homeostasis dysregulation [4–6,17], including
decreased SERCA pump activity, we investigated whether the SERCA
pump regulates glucose transport in the healthy and diabetic myocardi-
um. We found that SERCA1a expression in the heart substantially en-
hanced GLUT4 trafﬁcking. These improvements in cardiac GLUT4
trafﬁcking resulted in novel beneﬁts to glucose homeostasis, such that
cardiac-speciﬁc SERCA pump overexpression partially rescued the
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Fig. 5. Cardiac-speciﬁc SERCA1a expression increases cardiac glucose uptake in the
diabetic (Dx) heart. A) Representative image of the coronal view of myocardial
18
ﬂuorodeoxyglucose (FDG) activity assessedbymicropositron emission tomography1h fol-
lowing injection in a transgenic (TG) Dx mouse that fasted for 3 h prior to injection.
B) Representative images of the transverse view of 18FDG activity in the body cavity and
heart of one TGDx and its littermate Dxwildtype (WTDx). C)Mean±SE total 18FDGuptake
in the heart of healthy (Con) andDxWT and TGmice (n=5–6/group). Values represent the
content normalized to the initial injection dose. * P b 0.05 vs. WT Con, † P b 0.05 vs. WT Dx.
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that SERCA pump activation and/or enhanced intracellular calcium
ﬂux is a major regulator of glucose transport.
We usedmice expressing the SERCA1a pump in the heart, which in-
duced an increase in total SERCA pump protein expression by ~50% in
(healthy and diabetic) TG mice, similar to previous reports of both
SERCA-2a [4,6,7,25] and -1a [15,26] overexpression in healthy, diabetic
or hypertrophic hearts. However, ourmodel of cardiac-speciﬁc SERCA1a
expression offers some advantages over SERCA2a upregulation
including that increased SERCA1a activity does not signiﬁcantly en-
hance contractile strength at physiologic frequencies [15], nor increase
contractility or decrease relaxation time at baseline and after isoproter-
enol stimulation [26–28]. Consistent with these ﬁndings, we found no
signiﬁcant change in systolic (i.e., contractile) function in TGmice com-
pared to their WT littermates, despite the presence of mild increase in
LVPWd. In addition, because there is a close relationship between the
STZ dose and the severity of diabetes, we established a diabetic model
with relatively preserved systolic function by using a low dose of STZ
[5]. Therefore, this model allows us to study the regulation of glucose
uptake independently of cardiac contraction. In addition, expression of
SERCA1 in the heart by gene transfer resulted in a shift from fat to
carbohydrate utilization following β-adrenergic challenge, thereby
potentially making overall energy production more efﬁcient (in terms
of oxygen cost) [26]. Indeed, although fatty acids are the preferred sub-
strate for the heart, the shift toward increased glucose oxidation withSERCA overexpression sustained and enhanced the energetic state
(PCr/ATP) of healthy and hypertrophic hearts [26]. Importantly, meta-
bolic efﬁciency, in terms of glycolytic NADH transport into the mito-
chondria, was not compromised with the overexpression of SERCA1 in
healthy and hypertrophic hearts, and in fact it appears that the higher
mitochondrial calcium levels stimulate the calcium-sensitive pyruvate
dehydrogenase complex to increase pyruvate oxidation [26]. In con-
trast, in healthy mice overexpressing the SERCA2a isoform, hemody-
namic measurements revealed signiﬁcant increases in both contractile
rates and energy consumption, which manifest to compromised
energetics in hypertrophic hearts [25].
Although non-insulinmediated glucose uptake has been reported in
the isolatedworking rat heart [29], the role of Ca2+-mediated pathways
has primarily been investigated in the context of insulin-stimulated glu-
cose uptake and remains controversial [29–32]. Indeed, while many
studies have been adapted to study metabolism in the myocardium,
the quantiﬁcation of cell surface GLUT, which is critical to unravel the
molecular mechanisms regulating glucose transport, has proved very
challenging in mice, preventing the extensive use of TG models. For in-
stance, conventional membrane fractionation techniques are difﬁcult to
apply to mice because of the small size of the heart (b150mg). In addi-
tion, docking and fusion of GLUT4 with the cell surface membrane are
required steps after translocation to activate GLUTs, which cannot be
differentiated from inactive GLUTs (i.e., before fusion)with immunohis-
tochemistry and immunoﬂurorescence techniques. Further, studies
using neonatal cardiac myocytes, for which GLUT4 is only a minor
isoform, may not be physiologically relevant to intact adult myocytes.
Finally, the use of perfused heart is the preferred method for transport
studies compared to excised heart muscle and isolated cardiac
myocytes, because it uses an intact physiological preparation. Therefore,
in the present study, we used a state-of-the-art technique to measure
GLUT4 trafﬁcking in the intact photolabeled perfused heart. Although
ﬁrst described by Dr. Young's group [23], this innovative methodology
has never been used to unravel the molecular mechanisms controlling
GLUT trafﬁcking in the mouse heart under pathophysiological
conditions. Using this technique, we reported that cardiac-speciﬁc
SERCA1a expression enhanced active cell GLUT4 content in the intact
photolabeled perfused healthy heart. We further showed that pharma-
cologic agents that stimulate SERCA pump activity increased active cell
surface GLUT4 content in isolated photolabeled adult healthymyocytes,
with an opposite effect following incubation with the SERCA inhibitor
thapsigargin. During diabetes, insulin-stimulated GLUT4 translocation
was impaired, suggestive of impaired cardiac insulin signaling as previ-
ously reported in the STZ model [33]. Further, SERCA1a expression in
the diabetic heart rescued cardiac GLUT4 translocation, suggesting
that SERCA activity provides a main mechanism for cardiac glucose
transport in an insulin-deﬁcient state. Finally, our results showed that
cardiac speciﬁc SERCA1a expression normalized insulin-stimulated
GLUT4 trafﬁcking during diabetes, suggesting a potential independent
and additive effect of SERCA with insulin action. Therefore, both our
in vivo and in vitro results indicate that SERCA pump activity regulates
glucose transport in the healthy and diabetic myocardium indepen-
dently of insulin.
Although the downstream pathways by which impaired glucose
transport contributes to diabetes are still poorly understood in all
insulin-sensitive tissues, AS160 has emerged as a potential key player
of GLUT4 translocation during basal condition and insulin- and Ca2+/
contraction-stimulated conditions [8,9,34]. However, the mechanistic
role of AS160 in the heart during physiologic and pathophysiologic con-
ditions is not elucidated, thus underscoring the importance of timely
further study. In basal cells, most of the GLUT4 is sequestered into a
non-cycling/slowly cycling pool in specialized GLUT4 storage vesicles,
and the interaction of AS160 with these vesicles plays a key role in the
intracellular sequestration of GLUT4 in the basal state [34–36]. Indeed,
our data is consistent with a signiﬁcant inhibitory role of AS160 in the
basal state, such that decreased total AS160 content in healthy and Dx
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Fig. 6. Cardiac-speciﬁc SERCA1a expression enhances whole body glucose homeostasis. (A) Glucose tolerance was increased in healthy (Con) transgenic (TG)mice during an intraperito-
neal glucose tolerance test.Mean± SE venous blood [glucose] before (time 0) and during an intraperitoneal glucose tolerance test in healthy fastedwildtype (WT) and littermate TGmice
expressing SERCA1a pump in theheart (n=8/group). # P b 0.05 vs.WTmice. (B) SERCA overexpression in theheart of diabetic (Dx)mice partially rescues hyperglycemia during diabetes.
Mean ± SE venous fasting blood glucose concentration in healthy and diabetic WT and TG mice expressing SERCA1a in the heart, obtained at baseline (0) and up to 56 days after ﬁnal
streptozotocin or placebo injection (n = 7–18/group). † P b 0.05 vs. WT Dx, # P b 0.05 vs. baseline (0). Blood [glucose] was signiﬁcantly correlated with active cell surface GLUT4 and
total 18FDG uptake (independent variables) in the healthy and diabetic myocardium of WT and TG mice. (C) Scatterplot and linear regression of myocardial cell surface GLUT4 content
(independent variable) and venous blood [glucose] (dependent variable): P = 0.015, R2 = 0.208. [glucose] = 345.44 - (140.50 * GLUT4), n = 4–5. (D) Scatterplot and linear regression
of myocardial glucose uptake (independent variable) and venous blood [glucose] (dependent variable): P = 0.021, R2 = 0.276. [glucose] = 258.93 - (36.38 * total 18FDG uptake).
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myocardial cell surface GLUT4 (by 49 and 57%, respectively, P b 0.05),
similar to previous ﬁndings in healthy adipocytes [34]. In addition to
its inhibitory role during basal condition, it is now well established in
skeletalmuscle and adipose tissue that insulin activates AS160 via phos-
phorylation of at least 6 different phospho-Akt-substrate (PAS) sites,
which suppresses or alters GAP activity, thereby elevating the GTP
form of Rab, so GLUT4 exocytosis is permitted [37]. However, while
the majority of previous studies have investigated the phosphorylation
of AS160 on these PAS sites, it is becoming increasingly evident that the
investigation of phosphorylation state alone is insufﬁcient to enhance
our understanding of AS160 regulation and thus GLUT4 trafﬁcking, es-
pecially with regards to the insulin-independent pathways [19,21,38].
Indeed, we did not ﬁnd any signiﬁcant differences in phosphorylated
AS160 content in healthy and diabetic TG mice, suggesting that
SERCA1a expression regulates GLUT4 trafﬁcking in the heart through a
mechanism independent of the insulin/Akt signaling pathway. In
agreement with our ﬁndings, it has been shown in skeletal muscle
that AS160 possesses a distinct calmodulin binding site, the activation
of which by calmodulin is essential for full contraction- (but not
insulin-) stimulated glucose uptake in skeletal muscle, and which
regulates glucose uptake independently of PAS phosphorylation [8].
However, whether similar mechanism occurs in the heart is unknown.
Therefore, we also quantiﬁed the binding of CaM to AS160 using a cal-
modulin binding assay method that has been previously validated
with co-immunoprecipitation technique [8,21]. Our results showed an
increase in the proportion of CaM bound-AS160 in TG compared to
WT mice, such as CaM-AS160 was increased by 56 and 13% (P b 0.05)
in healthy and diabetic TGmice, respectively. Sincewe recently demon-
strated that SERCA1a expression in the heart increases the amplitude of
Ca2+ transient [16], the present ﬁndings suggest that cardiac-speciﬁcSERCA1a expression increases Ca2+–CaM binding, which in turn in-
creases AS160 activation since CaMmust be complexedwith Ca2+ to fa-
cilitate association with AS160 [21]. Therefore, the present study
investigates all three of these important aspects of AS160 function,
and thus, provides novel insights into the overall regulation of GLUT4
trafﬁcking by AS160 in the healthy and diabetic myocardium. Collec-
tively, our ﬁndings suggested that the decreased basal AS160 levels in
our healthy and diabetic TG mice increases cell surface GLUT4 by en-
hancing the actively cycling GLUT4 pool, and that the higher proportion
of CaMbound-AS160 in thesemicewould further enhanceGLUT4 trans-
location by increasing the amount of AS160 in the active (GAP
inhibited) state and thus increasing exocytosis.
An important ﬁnding in our studywas that cardiac-speciﬁc SERCA1a
expression not only enhanced cardiac glucose uptake, but also
enhancedwhole body glucose tolerance in healthymice.We further re-
ported that blood glucose concentration was signiﬁcantly correlated
with active cell surface GLUT4 and glucose uptake in the heart. Since
the rate of glucose utilization in the heart is greater than other insulin-
sensitive tissues, despite the ability of themyocardium to use other sub-
strates, in order to sustain the high energy demand [39], these ﬁndings
suggest that a shift in metabolic substrate from primarily fatty acid to
glucose utilization in the myocardium of TG mice could impact whole
body glucose homeostasis. In addition, Grueter and colleagues [40]
recently reported that the heart, which has the highest rate of oxygen
consumption per gram of any tissue in the body, plays an important
role in the control of energy homeostasis and adiposity through amech-
anism involving MED13 and miR-208a. Collectively, these results sug-
gest that the heart could play a role in modulating whole body energy
expenditure. Furthermore, during diabetes, our results indicated that
cardiac-speciﬁc SERCA1a expression not only increased myocardial
glucose transport but also partially rescued hyperglycemia. Thus, we
880 A.P. Waller et al. / Biochimica et Biophysica Acta 1852 (2015) 873–881successfully developed a TG animal model that is partly resistant to
diabetes. These ﬁndings further suggest that the SERCA pump in the
heart is a major regulator of not only cardiac but whole body glucose
homeostasis, consistent with recent studies in liver tissue which also
demonstrated that SERCA2b overexpression in the liver of obese mice
lowered blood glucose concentration and improved glucose tolerance
[41,42]. Taken together, these results suggest that activation of novel
insulin-independent pathways regulating glucose transport could
provide a much needed alternate therapeutic target for diabetic
patients, for many of whom proper control of hyperglycemia by
insulin-sensitizing therapy is lacking [43,44]. Since SERCA pump dys-
function contributes to the pathogenesis of diabetic cardiomyopathy, a
common and insidious complication, overexpression of the SERCA
pump is a promising gene therapy approach for the diabetic population
[5,17,45].
In conclusion, using in vivo and in vitro techniques, our data
suggested that the SERCA pump is a major regulator of cardiac glucose
transport, independently of insulin, and ultimatelymodulates peripher-
al glucose metabolism. These ﬁndings provide novel mechanistic
insights linking upregulation of the SERCA pump as a potential thera-
peutic target to restore glucose transport and potentially whole body
glucose homeostasis in diabetic patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.01.009.
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